PMS42 COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72195-7
https://www.valueinhealthjournal.com/article/S1098-3015(11)72195-7/fulltext
Title :
PMS42 COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72195-7&doi=10.1016/S1098-3015(11)72195-7
First page :
A310
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
355